[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intraoperative-neurophysiological-monitoring\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intraoperative-neurophysiological-monitoring":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100639092","low-dose-rocuronium-maintenance-during-spine-surgery-with-intraoperative-neurophysiological-monitoring-100639092",false,"NCT07627750","Low-Dose Rocuronium Maintenance During Spine Surgery With Intraoperative Neurophysiological Monitoring","A Randomized Controlled Trial Comparing Low-Dose Rocuronium Maintenance Versus Discontinuation After Induction on Motor Evoked Potential Quality During Spine Surgery With Intraoperative Neurophysiological Monitoring","ROC-IONM","Inclusion Criteria:\n\n\\- 1. Patients aged 18 years or older. 2. Patients scheduled for spine surgery under general anesthesia. 3. Patients undergoing spine surgery with intraoperative neurophysiological monitoring, including motor evoked potentials and\u002For somatosensory evoked potentials.\n\n4\\. Patients who agree to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Pre-existing central or peripheral neurological disease that may affect intraoperative neurophysiological monitoring, such as quadriplegia, persistent sensory disorder, sequelae of stroke, or polyneuropathy.\n\n  2\\. History of epilepsy or electroencephalographic disorder. 3. Use of neuropsychiatric drugs, strong sedatives, or drugs affecting neuromuscular or neurological conduction within 48 hours before surgery.\n\n  4\\. Decompensated cardiovascular disease or severe respiratory disease that may affect emergence or anesthetic drug metabolism.\n\n  5\\. Contraindication to intraoperative neurophysiological monitoring. 6. Contraindication to rocuronium. 7. Refusal to participate or withdrawal of consent at any time..","ALL","18 Years",{"count":20,"type":21},62,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized controlled trial will compare two strategies for rocuronium use during general anesthesia for spine surgery with intraoperative neurophysiological monitoring. Participants undergoing spine surgery under general anesthesia with motor evoked potential and\u002For somatosensory evoked potential monitoring will be randomized to either low-dose rocuronium maintenance targeting a train-of-four ratio of 0.60 to less than 0.90, or no rocuronium maintenance after induction.\n\nThe main objective is to compare the effects of these two strategies on the quality of intraoperative neurophysiological monitoring, especially motor evoked potential signals. Secondary objectives include comparing surgical field conditions, unwanted patient movement, emergence and extubation times, early respiratory events, and new postoperative neurological deficits.\n\nThe study will be conducted at the Center for Anesthesia and Surgical Intensive Care, Bach Mai Hospital, Hanoi, Vietnam. The planned sample size is 62 participants, with 31 participants in each group.",[27,28,29],"Spine Surgery","Intraoperative Neurophysiological Monitoring","Neuromuscular Blockade",[31,32,33,34,27,28,35],"Rocuronium","Motor Evoked Potentials","Somatosensory Evoked Potentials","Train-of-Four Ratio","Total Intravenous Anesthesia","NOT_YET_RECRUITING","2026-05-30",{"date":39,"type":40},"2026-06-04","ACTUAL",{"date":42,"type":21},"2026-06",{"date":44,"type":21},"2028-12",{"name":46,"class":47},"Bach Mai Hospital","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100434562","phase-4-effect-of-magnesium-sulfate-bolus-on-intraoperative-neuromonitoring-100434562","NCT04938765","Effect of Magnesium Sulfate Bolus on Intraoperative Neuromonitoring","Randomized and Placebo Controlled Study to Evaluate the Effect of Magnesium Sulfate on Intraoperative Neuromonitoring.","Inclusion Criteria.\n\n* Patients aged 18 to 80 years\n* Belonging to American Society of Anesthesiologists physical status (ASA) I, II\n* Undergoing elective spine or cranial surgery where intraoperative neuromonitoring including short latency somatosensory evoked potentials (SSEP or SEP) and transcranial electrical muscle motor evoked potentials recording from muscles (TceMEP or TcMEP or mMEP or MEP) is planned.\n\nExclusion Criteria:\n\n* Magnesium use within the last 2 days, either intravenous or oral supplements.\n* Patients with known electrolyte imbalances (Sodium \\\u003C135 or \\>145 mmol\u002FL OR Potassium \\\u003C 3.5 or \\> 5.0 mmol\u002FL, Magnesium \\>1.2 mmol\u002FL.\n* Severe cardiac or cardiac conduction disorders.\n* Severe pulmonary disease.\n* Patients with significant neuromuscular disorders or preexisting motor or sensory deficits other than focal upper limb neuropathy or focal cervical radiculopathy or mild cervical myelopathy.\n* Severe Renal disease - serum creatinine of \\> 2 mg\u002Fdl.\n* Pregnant or breastfeeding patients.\n* Unable to obtain adequate baseline SSEPs and MEPs.","80 Years",{"count":57,"type":21},50,[59],"PHASE4","Magnesium Sulfate(MgSo4) is increasingly being used as part of the multimodal pain regimen in the perioperative period. The intraoperative neurophysiological monitoring (IONM) is utilized in complex spine and cranial surgeries to assess the functional integrity of the neural pathways. The effect of Magnesium sulfate on IONM has not been studied.\n\nThis is a prospective, double blind, randomized placebo controlled trial to study the effect of Magnesium sulfate bolus on the amplitude and latency of somatosensory(SSEPs) and motor evoked potentials(MEPs) in patients undergoing surgery requiring IONM.",[28,62],"Magnesium Sulfate",[64],"multimodal analgesia","RECRUITING","2026-04-21",{"date":68,"type":40},"2026-04-24",{"date":70,"type":40},"2022-03-18",{"date":72,"type":21},"2027-03",{"name":74,"class":47},"Loma Linda University",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":75},"100634724","mindz---minimally-invasive-approach-pilot-study-100634724","NCT07543406","MINDZ-- Minimally Invasive Approach Pilot Study","MINDZ-- Minimally Invasive Approach Pilot Study Single Center, First-in-Human Evaluation of MINDZ Electrode- Demonstrating the Feasibility of Safe, Burr-hole Deployment and Functional Efficacy","MINDZ-MAP","Inclusion Criteria:\n\n* Age ≥18 and ≤75 years at the time of enrolment.\n* Patients diagnosed with a brain tumour or epilepsy who require neurosurgical intervention. This includes patients undergoing craniotomy for brain surgery without the need for intracranial electrode monitoring, as well as patients undergoing neurosurgery with intraoperative neurophysiological monitoring using subdural electrodes. Specifically, this includes patients for whom subdural strip electrodes are indicated and planned to be implanted through standard-size burr holes (e.g., for phase-reversal evaluation)\n* Participants capable and willing to provide informed consent for participation in the trial.\n\nExclusion Criteria:\n\n* History of significant psychiatric impairments which, in the opinion of the investigator, will interfere with the proper administration or completion of the protocol.\n* Any medical condition that contradicts neurosurgical intervention (i.e., acute or ongoing untreated infections, anticoagulant medication that cannot be discontinued, factor XIII deficiency or any other hematological disease).\n* Participation in another clinical study.\n* Known intolerances to the materials used in the soft device (medical grade silicone or platinum).\n* Vulnerable subject groups (e.g., pregnancy or lactation, prisoners, etc.).\n* Any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.","75 Years",{"count":86,"type":21},5,[24],"This clinical investigation is a pilot, first-in-human (FIH) study designed to demonstrate proof of concept, safety, and functional performance of the MINDZ subdural electrode grid when used in relevant neurosurgical settings. The study will provide initial clinical evidence to support future conformity assessment and CE marking under the European Medical Device Regulation (MDR).\n\nThe investigational device, MINDZ, developed by Neurosoft Bioelectronics, is a novel, soft and highly conformable subdural electrode grid designed for minimally invasive implantation through a burr hole. Its flexible structure is intended to improve conformity to the cortical surface, reduce dead space between the electrode and brain tissue, and potentially lower the risk of complications associated with craniotomy, while maintaining adequate cortical coverage for effective monitoring and mapping.",[28],[91,92],"cortical electrode","IONM","2026-04-15",{"date":66,"type":40},{"date":96,"type":21},"2026-05-01",{"date":98,"type":21},"2027-06-01",{"name":100,"class":101},"Neurosoft Bioelectronics SA","INDUSTRY"]